drugset / Trial / NCT00807963

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

NCT00807963

Phase 1 Completed 31 enrolled Halozyme Therapeutics
RandomizedSingle-groupSingle-blindOther

Summary

The purpose of this study is to determine the maximum tolerated concentration (MTC) of bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate without rHuPH20 administered SC, the optimal dose of rHuPH20 to deliver bisphosphonate SC at MTC, and to compare the PK of SC administered bisphosphonate at MTC with optimal dose rHuPH20 to bisphosphonate alone.

Timeline

Start
2008-12
Primary completion
2009-09-21
Completion
2009-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg Subcutaneous
Subject rHuPH20 Protein / enzyme biologic Subcutaneous

Indications